Vanda Pharmaceuticals (VNDA) Receives Buy Rating from Oppenheimer

Vanda Pharmaceuticals (NASDAQ:VNDA)‘s stock had its “buy” rating reaffirmed by equities researchers at Oppenheimer in a research report issued to clients and investors on Sunday, November 12th. They presently have a $25.00 price objective on the biopharmaceutical company’s stock. Oppenheimer’s target price would indicate a potential upside of 80.25% from the stock’s previous close. Oppenheimer also issued estimates for Vanda Pharmaceuticals’ Q3 2018 earnings at $0.00 EPS and Q4 2018 earnings at $0.04 EPS.

VNDA has been the topic of several other research reports. Zacks Investment Research raised shares of Vanda Pharmaceuticals from a “sell” rating to a “strong-buy” rating and set a $18.00 price objective on the stock in a research report on Tuesday, August 8th. BidaskClub lowered shares of Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. Piper Jaffray Companies set a $23.00 price target on Vanda Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, August 3rd. HC Wainwright set a $18.00 price target on Vanda Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, August 3rd. Finally, ValuEngine downgraded Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, October 26th. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. Vanda Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $21.50.

Shares of Vanda Pharmaceuticals (VNDA) traded down $0.18 on Friday, reaching $13.87. 354,393 shares of the company traded hands, compared to its average volume of 552,875. Vanda Pharmaceuticals has a 52-week low of $11.90 and a 52-week high of $18.99.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, meeting the consensus estimate of ($0.10). The firm had revenue of $41.30 million for the quarter, compared to analyst estimates of $43.90 million. Vanda Pharmaceuticals had a negative net margin of 9.01% and a negative return on equity of 10.99%. The company’s revenue for the quarter was up 7.3% on a year-over-year basis. During the same quarter last year, the firm earned ($0.01) earnings per share. equities analysts expect that Vanda Pharmaceuticals will post -0.42 EPS for the current year.

Hedge funds have recently made changes to their positions in the business. Legal & General Group Plc grew its stake in shares of Vanda Pharmaceuticals by 37.4% in the second quarter. Legal & General Group Plc now owns 11,105 shares of the biopharmaceutical company’s stock worth $181,000 after acquiring an additional 3,022 shares during the last quarter. Kopp Investment Advisors LLC acquired a new stake in shares of Vanda Pharmaceuticals in the second quarter worth $196,000. Los Angeles Capital Management & Equity Research Inc. acquired a new stake in shares of Vanda Pharmaceuticals in the third quarter worth $277,000. Voya Investment Management LLC grew its stake in shares of Vanda Pharmaceuticals by 29.7% in the second quarter. Voya Investment Management LLC now owns 20,118 shares of the biopharmaceutical company’s stock worth $328,000 after acquiring an additional 4,605 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd grew its stake in shares of Vanda Pharmaceuticals by 46.3% in the second quarter. Dynamic Technology Lab Private Ltd now owns 20,510 shares of the biopharmaceutical company’s stock worth $335,000 after acquiring an additional 6,487 shares during the last quarter. Institutional investors own 88.45% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Vanda Pharmaceuticals (VNDA) Receives Buy Rating from Oppenheimer” was originally published by BBNS and is owned by of BBNS. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://baseballnewssource.com/markets/oppenheimer-holdings-inc-reaffirms-buy-rating-for-vanda-pharmaceuticals-inc-vnda/1779514.html.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Analyst Recommendations for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Manny Machado Could Change Positions or Uniforms
Manny Machado Could Change Positions or Uniforms
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot
Angels Sign Former Prospect with Braves Kevin Maitan
Angels Sign Former Prospect with Braves Kevin Maitan


Leave a Reply

 
© 2006-2017 BBNS.